<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35020530</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media.</ArticleTitle>
        <Pagination>
          <StartPage>2013693</StartPage>
          <MedlinePgn>2013693</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2013693</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.2013693</ELocationID>
        <Abstract>
          <AbstractText>Otitis media (OM) is a common disease of childhood and available pneumococcal conjugate vaccines (PCVs), with different compositions, could have different impact on OM reduction. This systematic literature review evaluated available data describing the efficacy, effectiveness, and impact of 10-valent pneumococcal <i>Haemophilus influenzae</i> protein D conjugate vaccine (PHiD-CV) and 13-valent PCV (PCV13) on OM outcomes. Statistically significant reductions in all-cause and complicated OM, tympanostomy tube placement and OM-related hospitalizations were consistently observed after the introduction of PHiD-CV and PCV13. Impact studies with data in children &lt;2 years of age using PCV13 report 47-51% and PHiD-CV 34-43% reduction of all-cause OM (primary care, outpatient, ambulatory, emergency department visits) compared to periods before PCV introduction. When the impact of both vaccines is assessed in comparable settings, some studies suggest PHiD-CV may offer better protection against some OM outcomes. Well-designed, head-to-head comparisons are needed to better understand the differences and guide vaccination policies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Izurieta</LastName>
            <ForeName>Patricia</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0001-5703-3151</Identifier>
            <AffiliationInfo>
              <Affiliation>GSK, Wavre, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scherbakov</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-9189-4729</Identifier>
            <AffiliationInfo>
              <Affiliation>GSK, Moscow, Russian Federation.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nieto Guevara</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-3073-2830</Identifier>
            <AffiliationInfo>
              <Affiliation>GSK, Panama City, Panama.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vetter</LastName>
            <ForeName>Volker</ForeName>
            <Initials>V</Initials>
            <Identifier Source="ORCID">0000-0002-8414-1657</Identifier>
            <AffiliationInfo>
              <Affiliation>GSK, Wavre, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soumahoro</LastName>
            <ForeName>Lamine</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-2166-7926</Identifier>
            <AffiliationInfo>
              <Affiliation>GSK, Wavre, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018074">Vaccines, Conjugate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010033" MajorTopicYN="Y">Otitis Media</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011008" MajorTopicYN="Y">Pneumococcal Infections</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018074" MajorTopicYN="N">Vaccines, Conjugate</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Type="plain-language-summary" Language="eng">
        <AbstractText>Plain Language Summary<b>What is the context?</b>Pneumococcal vaccines are highly effective in preventing pneumonia and meningitis in children. The two main pneumococcal vaccines are PHiD-CV (<i>Synflorix</i>, GSK) and PCV13 (<i>Prevenar 13</i>, Pfizer). Both vaccines have been shown to provide protection against otitis media despite differing in their composition.However, it is currently unknown if both vaccines confer similar level of protection against otitis media.<b>What is new?</b>We conducted a literature review to evaluate the effects of PHiD-CV and PCV13 on otitis media.From 33 articles, we found that:‡Both vaccines were effective in reducing doctor visits for otitis media as well as the number of severe cases and cases requiring hospitalization.‡Four studies suggested a higher level of protection provided by PHiD-CV compared to PCV13, although more data is needed to confirm this finding. <b>What is the impact?</b>Available information shows that PHiD-CV and PCV13 are effective in preventing a proportion of otitis media during childhood.Given the remaining substantial burden associated with the disease and the related significant usage of antibiotics, the development of improved vaccines with higher impact on otitis media would be welcome.</AbstractText>
      </OtherAbstract>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">effectiveness</Keyword>
        <Keyword MajorTopicYN="Y">impact</Keyword>
        <Keyword MajorTopicYN="Y">incidence</Keyword>
        <Keyword MajorTopicYN="Y">otitis media</Keyword>
        <Keyword MajorTopicYN="Y">pneumococcal conjugate vaccine</Keyword>
        <Keyword MajorTopicYN="Y">systematic literature review</Keyword>
        <Keyword MajorTopicYN="Y">vaccine</Keyword>
      </KeywordList>
      <CoiStatement>P Izurieta, M Scherbakov, J Nieto Guevara, V Vetter, and L Soumahoro are employees of the GSK group of companies and declare financial (including shares) and non-financial relationships and activities.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
          <Hour>17</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35020530</ArticleId>
        <ArticleId IdType="pmc">PMC8973322</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2021.2013693</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tin Tin Htar M, van Den Biggelaar AHJ, Sings H, Ferreira G, Moffatt M, Hall-Murray C, Verstraeten T, Gessner BD, Schmitt H-J, Jodar L, et al. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review. Expert Rev Vaccines. 2019;18(10):1069–18. doi:10.1080/14760584.2019.1676155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14760584.2019.1676155</ArticleId>
            <ArticleId IdType="pubmed">31585049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiese AD, Griffin MR, Grijalva CG.. 
Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Rev Vaccines. 2019;18:327–41. doi:10.1080/14760584.2019.1582337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14760584.2019.1582337</ArticleId>
            <ArticleId IdType="pmc">PMC6443450</ArticleId>
            <ArticleId IdType="pubmed">30759352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen R, Cohen JF, Chalumeau M, Levy C. Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries. Expert Rev Vaccines. 2017;16:625–40. doi:10.1080/14760584.2017.1320221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14760584.2017.1320221</ArticleId>
            <ArticleId IdType="pubmed">28409537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alicino C, Paganino C, Orsi A, Astengo M, Trucchi C, Icardi G, Ansaldi F. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: a systematic review and meta-analysis. Vaccine. 2017;35:5776–85. doi:10.1016/j.vaccine.2017.09.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.09.005</ArticleId>
            <ArticleId IdType="pubmed">28911902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckley BS, Henschke N, Bergman H, Skidmore B, Klemm EJ, Villanueva G, Garritty C, Paul M. Impact of vaccination on antibiotic usage: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25:1213–25. doi:10.1016/j.cmi.2019.06.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmi.2019.06.030</ArticleId>
            <ArticleId IdType="pubmed">31284031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Oliveira LH, Shioda K, Valenzuela MT, Janusz CB, Rearte A, Sbarra AN, Warren JL, Toscano CM, Weinberger DM. Declines in pneumonia mortality following the introduction of pneumococcal conjugate vaccines in Latin American and Caribbean countries. Clin Infect Dis. 2021;73(2):306–13. doi:10.1093/cid/ciaa614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciaa614</ArticleId>
            <ArticleId IdType="pmc">PMC8516507</ArticleId>
            <ArticleId IdType="pubmed">32448889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsaban G, Ben-Shimol S. Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: a systematic review of the literature. Vaccine. 2017;35:2882–91. doi:10.1016/j.vaccine.2017.04.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.04.032</ArticleId>
            <ArticleId IdType="pubmed">28449971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loo JD, Conklin L, Fleming-Dutra KE, Knoll MD, Park DE, Kirk J, Goldblatt D, O’Brien KL, Whitney CG. Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J. 2014;33(Suppl 2):S161–71. doi:10.1097/INF.0000000000000084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0000000000000084</ArticleId>
            <ArticleId IdType="pmc">PMC3940524</ArticleId>
            <ArticleId IdType="pubmed">24336058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berman-Rosa M, O’Donnell S, Barker M, Quach C. Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease. Pediatrics. 2020;145:e20190377. doi:10.1542/peds.2019-0377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2019-0377</ArticleId>
            <ArticleId IdType="pubmed">32156773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Rev Vaccines. 2018;17:479–93. doi:10.1080/14760584.2018.1413354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14760584.2018.1413354</ArticleId>
            <ArticleId IdType="pubmed">29241390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vojtek I, Nordgren M, Hoet B. Impact of pneumococcal conjugate vaccines on otitis media: a review of measurement and interpretation challenges. Int J Pediatr Otorhinolaryngol. 2017;100:174–82. doi:10.1016/j.ijporl.2017.07.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijporl.2017.07.009</ArticleId>
            <ArticleId IdType="pubmed">28802367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newhouse, L.
PATH new pneumococcal vaccine from Serum Institute of India achieves WHO prequalification. 2019. 
Dec
19 [accessed 2020 Aug
21]. https://www.path.org/media-center/new-pneumococcal-vaccine-serum-institute-india-achieves-who-prequalification/</Citation>
        </Reference>
        <Reference>
          <Citation>de Oliveira LH, Camacho LA, Coutinho ESF, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C, Toscano CM. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. PLoS One. 2016;11(12):e0166736. doi:10.1371/journal.pone.0166736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0166736</ArticleId>
            <ArticleId IdType="pmc">PMC5152835</ArticleId>
            <ArticleId IdType="pubmed">27941979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen O, Knoll M, O’Brien K, Ramakrishnan M, Constenla D, Privor-Dumm L, Buss-Younkin J, Farrar J, Pilishvili T, Whitney C. Pneumococcal conjugate vaccine (PCV) product assessment 2017 April. [accessed 2020 Jul
10]. https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>McGirr A, Iqbal SM, Izurieta P, Talarico C, Luijken J, Redig J, Newson RS. A systematic literature review and network meta-analysis feasibility study to assess the comparative efficacy and comparative effectiveness of pneumococcal conjugate vaccines. Hum Vaccin Immunother. 2019;15(11):2713–24. doi:10.1080/21645515.2019.1612667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2019.1612667</ArticleId>
            <ArticleId IdType="pmc">PMC6930063</ArticleId>
            <ArticleId IdType="pubmed">31216216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902. doi:10.1016/S0140-6736(09)61204-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(09)61204-6</ArticleId>
            <ArticleId IdType="pubmed">19748398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fortanier AC, Venekamp RP, Boonacker CW, Hak E, Schilder AG, Sanders EA, Damoiseaux RA. Pneumococcal conjugate vaccines for preventing acute otitis media in children. Cochrane Database Syst Rev. 2019;5:Cd001480. doi:10.1002/14651858.CD001480.pub5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD001480.pub5</ArticleId>
            <ArticleId IdType="pmc">PMC6537667</ArticleId>
            <ArticleId IdType="pubmed">31135969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J. 2004;23:1142–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15626953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke C, Bakaletz LO, Ruiz-Guinazu J, Borys D, Mrkvan T. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage. Expert Rev Vaccines. 2017;16:1–14. doi:10.1080/14760584.2017.1333905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14760584.2017.1333905</ArticleId>
            <ArticleId IdType="pubmed">28571504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saez-Llorens X, Rowley S, Wong D, Rodriguez M, Calvo A, Troitino M, Salas A, Vega V, Castrejón MM, Lommel P. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children – a randomized controlled trial. Hum Vaccin Immunother. 2017;13:1–16. doi:10.1080/21645515.2017.1287640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2017.1287640</ArticleId>
            <ArticleId IdType="pmc">PMC5489287</ArticleId>
            <ArticleId IdType="pubmed">28368738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6):e1001657. doi:10.1371/journal.pmed.1001657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1001657</ArticleId>
            <ArticleId IdType="pmc">PMC4043495</ArticleId>
            <ArticleId IdType="pubmed">24892763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Herva E, Takala A, Käyhty H, Karma P, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403–09. doi:10.1056/NEJM200102083440602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM200102083440602</ArticleId>
            <ArticleId IdType="pubmed">11172176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmu AA, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, Moreira M, Schuerman L, Borys D, Kilpi TM, et al. Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial. Vaccine. 2018;36(14):1816–22. doi:10.1016/j.vaccine.2018.02.088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2018.02.088</ArticleId>
            <ArticleId IdType="pubmed">29503110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Sevaux JL, Venekamp RP, Lutje V, Hak E, Schilder AG, Sanders EA, Damoiseaux RA. Pneumococcal conjugate vaccines for preventing acute otitis media in children. Cochrane Database Syst Rev. 2020;11:CD001480. doi:10.1002/14651858.CD001480.pub6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD001480.pub6</ArticleId>
            <ArticleId IdType="pmc">PMC8096893</ArticleId>
            <ArticleId IdType="pubmed">33231293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. doi:10.1186/s13643-016-0384-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13643-016-0384-4</ArticleId>
            <ArticleId IdType="pmc">PMC5139140</ArticleId>
            <ArticleId IdType="pubmed">27919275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sterne JAC, Hernán MA, McAleenan A, Reeves BC, Higgins JPT. Chapter 25: assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane; 2019. https://methods.cochrane.org/methods-cochrane/robins-i-tool.</Citation>
        </Reference>
        <Reference>
          <Citation>Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane; 2019. https://methods.cochrane.org/risk-bias-2.</Citation>
        </Reference>
        <Reference>
          <Citation>Palmu AA, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, Traskine M, Moreira M, Borys D, Schuerman L. Effectiveness of the ten-valent pneumococcal conjugate vaccine against tympanostomy tube placements in a cluster-randomized trial. Pediatr Infect Dis J. 2015;34(11):1230–35. doi:10.1097/inf.0000000000000857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000000857</ArticleId>
            <ArticleId IdType="pubmed">26284652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karppinen S, Toivonen L, Schuez-Havupalo L, Teros-Jaakkola T, Waris M, Auranen K, Palmu AA, Peltola V. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age. Vaccine. 2019;37:2935–41. doi:10.1016/j.vaccine.2019.04.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2019.04.026</ArticleId>
            <ArticleId IdType="pubmed">31027929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pichichero M, Kaur R, Scott DA, Gruber WC, Trammel J, Almudevar A, Center KJ. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. Lancet Child Adolesc Health. 2018;2(8):561–68. doi:10.1016/s2352-4642(18)30168-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s2352-4642(18)30168-8</ArticleId>
            <ArticleId IdType="pubmed">30119715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ochoa-Gondar O, Figuerola-Massana E, Vila-Corcoles A, Aguirre CA, de Diego C, Satue E, Gomez F, Raga X. Epidemiology of Streptococcus pneumoniae causing acute otitis media among children in Southern Catalonia throughout 2007-2013: incidence, serotype distribution and vaccine’s effectiveness. Int J Pediatr Otorhinolaryngol. 2015;79:2104–08. doi:10.1016/j.ijporl.2015.09.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijporl.2015.09.022</ArticleId>
            <ArticleId IdType="pubmed">26453272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sohn S, Hong K, Chun BC. Evaluation of the effectiveness of pneumococcal conjugate vaccine for children in Korea with high vaccine coverage using a propensity score matched national population cohort. Int J Infect Dis. 2020;93:146–50. doi:10.1016/j.ijid.2020.01.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2020.01.034</ArticleId>
            <ArticleId IdType="pubmed">31982620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lau WC, Murray M, El-Turki A, Saxena S, Ladhani S, Long P, Sharland M, Wong ICK, Hsia Y. Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom. Vaccine. 2015;33(39):5072–79. doi:10.1016/j.vaccine.2015.08.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2015.08.022</ArticleId>
            <ArticleId IdType="pubmed">26297875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiese AD, Huang X, Yu C, Mitchel EF, Kyaw MH, Griffin MR, Grijalva CG. Changes in otitis media episodes and pressure equalization tube insertions among young children following introduction of the 13-valent pneumococcal conjugate vaccine: a birth-cohort based study. Clin Infect Dis. 2019;69:2162–69. doi:10.1093/cid/ciz142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciz142</ArticleId>
            <ArticleId IdType="pubmed">30770533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X, de Luise C, Gaffney M, Burt CW, Scott DA, Gatto N, Center KJ. National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States. Int J Pediatr Otorhinolaryngol. 2019;119:96–102. doi:10.1016/j.ijporl.2019.01.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijporl.2019.01.023</ArticleId>
            <ArticleId IdType="pubmed">30690309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawai K, Adil EA, Barrett D, Manganella J, Kenna MA. Ambulatory visits for otitis media before and after the introduction of pneumococcal conjugate vaccination. J Pediatr. 2018;201:122–127.e1. doi:10.1016/j.jpeds.2018.05.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2018.05.047</ArticleId>
            <ArticleId IdType="pubmed">29958675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fortanier AC, Venekamp RP, Hoes AW, Schilder AGM. Does pneumococcal conjugate vaccination affect onset and risk of first acute otitis media and recurrences? A primary care-based cohort study. Vaccine. 2019;37:1528–32. doi:10.1016/j.vaccine.2019.01.064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2019.01.064</ArticleId>
            <ArticleId IdType="pubmed">30738648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigurdsson S, Eythorsson E, Hrafnkelsson B, Erlendsdottir H, Kristinsson KG, Haraldsson A. Reduction in all-cause acute otitis media in children &lt;3 years of age in primary care following vaccination with 10-valent pneumococcal haemophilus influenzae protein-D conjugate vaccine: a whole-population study. Clin Infect Dis. 2018;67:1213–19. doi:10.1093/cid/ciy233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciy233</ArticleId>
            <ArticleId IdType="pubmed">29617959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sartori AL, Minamisava R, Bierrenbach AL, Toscano CM, Afonso ET, Morais-Neto OL, Antunes JLF, Cristo EB, Andrade AL. Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil. PLoS One. 2017;12(6):e0179222. doi:10.1371/journal.pone.0179222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0179222</ArticleId>
            <ArticleId IdType="pmc">PMC5464612</ArticleId>
            <ArticleId IdType="pubmed">28594913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenblut A, Rosenblut M, Garcia K, Maul X, Santolaya ME. Frequency of acute otitis media in children under 24 months of age before and after the introduction of the 10-valent pneumococcal conjugate vaccine into the national immunization program in Chile. Pediatr Infect Dis J. 2018;37:132–34. doi:10.1097/inf.0000000000001722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000001722</ArticleId>
            <ArticleId IdType="pubmed">28763425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suarez V, Michel F, Toscano CM, Bierrenbach AL, Gonzales M, Alencar AP, Ruiz Matus C, Andrus JK, de Oliveira LH. Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: time series analyses. Vaccine. 2016;34:4738–43. doi:10.1016/j.vaccine.2016.07.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2016.07.027</ArticleId>
            <ArticleId IdType="pubmed">27521230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marom T, Bookstein Peretz S, Schwartz O, Goldfarb A, Oron Y, Tamir SO. Impact of pneumococcal conjugate vaccines on selected head and neck infections in hospitalized Israeli children. Pediatr Infect Dis J. 2017;36:314–18. doi:10.1097/inf.0000000000001425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000001425</ArticleId>
            <ArticleId IdType="pubmed">27879558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laursen BB, Danstrup CS, Hoffmann S, Norskov-Lauritsen N, Christensen ALB, Ovesen T. The effect of pneumococcal conjugate vaccines on incidence and microbiology associated with complicated acute otitis media. Int J Pediatr Otorhinolaryngol. 2017;101:249–53. doi:10.1016/j.ijporl.2017.07.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijporl.2017.07.002</ArticleId>
            <ArticleId IdType="pubmed">28964304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tawfik KO, Ishman SL, Altaye M, Meinzen-Derr J, Choo DI. Pediatric acute otitis media in the era of pneumococcal vaccination. Otolaryngol Head Neck Surg. 2017;156:938–45. doi:10.1177/0194599817699599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0194599817699599</ArticleId>
            <ArticleId IdType="pubmed">28349737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fortunato F, Martinelli D, Cappelli MG, Cozza V, Prato R. Impact of pneumococcal conjugate universal routine vaccination on pneumococcal disease in Italian children. J Immunol Res. 2015;2015:206757. doi:10.1155/2015/206757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/206757</ArticleId>
            <ArticleId IdType="pmc">PMC4553180</ArticleId>
            <ArticleId IdType="pubmed">26351644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leach AJ, Wigger C, Andrews R, Chatfield M, Smith-Vaughan H, Morris PS. Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules. BMC Pediatr. 2014;14:200. doi:10.1186/1471-2431-14-200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2431-14-200</ArticleId>
            <ArticleId IdType="pmc">PMC4149294</ArticleId>
            <ArticleId IdType="pubmed">25109288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigurdsson S, Eythorsson E, Erlendsdottir H, Hrafnkelsson B, Kristinsson KG, Haraldsson A. Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland. Vaccine. 2020;38:2707–14. doi:10.1016/j.vaccine.2020.01.094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2020.01.094</ArticleId>
            <ArticleId IdType="pubmed">32063434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petousis-Harris H, Howe AS, Paynter J, Turner N, Griffin J. Pneumococcal conjugate vaccines turning the tide on inequity: a retrospective cohort study of New Zealand children born 2006-2015. Clin Infect Dis. 2019;68:818–26. doi:10.1093/cid/ciy570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciy570</ArticleId>
            <ArticleId IdType="pubmed">30032236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Shimol S, Givon-Lavi N, Leibovitz E, Greenberg D, Dagan R. Studying PCV impact on clinical presentation of otitis media helps to understand its pathogenesis. Vaccine. 2019;37:1–6. doi:10.1016/j.vaccine.2018.11.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2018.11.054</ArticleId>
            <ArticleId IdType="pubmed">30497832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Impact of widespread introduction of pneumococcal conjugate vaccines on pneumococcal and nonpneumococcal otitis media. Clin Infect Dis. 2016;63:611–18. doi:10.1093/cid/ciw347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciw347</ArticleId>
            <ArticleId IdType="pubmed">27225239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clin Infect Dis. 2014;59:1724–32. doi:10.1093/cid/ciu683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciu683</ArticleId>
            <ArticleId IdType="pubmed">25159581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmu AA, Rinta-Kokko H, Nohynek H, Nuorti JP, Jokinen J. Impact of national ten-valent pneumococcal conjugate vaccine program on reducing antimicrobial use and tympanostomy tube placements in Finland. Pediatr Infect Dis J. 2018;37:97–102. doi:10.1097/inf.0000000000001810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000001810</ArticleId>
            <ArticleId IdType="pubmed">29088026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eythorsson E, Sigurdsson S, Erlendsdottir H, Hrafnkelsson B, Kristinsson KG, Haraldsson A. Increase in tympanostomy tube placements despite pneumococcal vaccination, a population-based study. Acta Paediatr. 2019;108:1527–34. doi:10.1111/apa.14724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apa.14724</ArticleId>
            <ArticleId IdType="pmc">PMC6767502</ArticleId>
            <ArticleId IdType="pubmed">30667099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gisselsson-Solen M. Trends in otitis media incidence after conjugate pneumococcal vaccination: a national observational study. Pediatr Infect Dis J. 2017;36:1027–31. doi:10.1097/inf.0000000000001654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000001654</ArticleId>
            <ArticleId IdType="pubmed">28657970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edmondson-Jones M, Dibbern T, Hultberg M, Anell B, Medin E, Feng Y, Talarico C. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions. Hum Vaccin Immunother. 2021;17:517–26. doi:10.1080/21645515.2020.1775455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2020.1775455</ArticleId>
            <ArticleId IdType="pmc">PMC7899701</ArticleId>
            <ArticleId IdType="pubmed">32574101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leach AJ, Wigger C, Beissbarth J, Woltring D, Andrews R, Chatfield MD, Smith-Vaughan H, Morris PS. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in northern territory aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines. Int J Pediatr Otorhinolaryngol. 2016;86:224–32. doi:10.1016/j.ijporl.2016.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijporl.2016.05.011</ArticleId>
            <ArticleId IdType="pubmed">27260611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J, Kim KH, Jo DS, Ma SH, Kim JH, Kim CS, Kim HM, Kang JH. A longitudinal hospital-based epidemiology study to assess acute otitis media incidence and nasopharyngeal carriage in Korean children up to 24 months. Hum Vaccin Immunother. 2020;16:3090–97. doi:10.1080/21645515.2020.1748978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2020.1748978</ArticleId>
            <ArticleId IdType="pmc">PMC8641589</ArticleId>
            <ArticleId IdType="pubmed">32330397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vesikari T, Forsten A, Seppa I, Kaijalainen T, Puumalainen T, Soininen A, Traskine M, Lommel P, Schoonbroodt S, Hezareh M, et al. Effectiveness of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D–conjugated vaccine (PHiD-CV) against carriage and acute otitis media – a double-blind randomized clinical trial in Finland. J Pediatr Infect Dis Soc. 2016;5:237–48. doi:10.1093/jpids/piw010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jpids/piw010</ArticleId>
            <ArticleId IdType="pmc">PMC5125453</ArticleId>
            <ArticleId IdType="pubmed">27125273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eythorsson E, Sigurdsson S, Hrafnkelsson B, Erlendsdottir H, Haraldsson A, Kristinsson KG. Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study. BMC Infect Dis. 2018;18:505. doi:10.1186/s12879-018-3416-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12879-018-3416-y</ArticleId>
            <ArticleId IdType="pmc">PMC6172799</ArticleId>
            <ArticleId IdType="pubmed">30286726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eythorsson E, Hrafnkelsson B, Erlendsdottir H, Gudmundsson SA, Kristinsson KG, Haraldsson A. Decreased acute otitis media with treatment failure after introduction of the ten-valent pneumococcal Haemophilus influenzae Protein D conjugate vaccine. Pediatr Infect Dis J. 2018;37:361–66. doi:10.1097/inf.0000000000001870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000001870</ArticleId>
            <ArticleId IdType="pubmed">29278616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong K, Coates HL. Natural history, definitions, risk factors and burden of otitis media. Med J Aust. 2009;191:S39–43. doi:10.5694/j.1326-5377.2009.tb02925.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5694/j.1326-5377.2009.tb02925.x</ArticleId>
            <ArticleId IdType="pmc">PMC7168379</ArticleId>
            <ArticleId IdType="pubmed">19883355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, Schuerman L. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006;367:740–48. doi:10.1016/S0140-6736(06)68304-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(06)68304-9</ArticleId>
            <ArticleId IdType="pubmed">16517274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fletcher MA, Fritzell B. Pneumococcal conjugate vaccines and otitis media: an appraisal of the clinical trials. Int J Otolaryngol. 2012;2012:312935. doi:10.1155/2012/312935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/312935</ArticleId>
            <ArticleId IdType="pmc">PMC3371682</ArticleId>
            <ArticleId IdType="pubmed">22701486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffiths UK, Clark A, Gessner B, Miners A, Sanderson C, Sedyaningsih ER, Mulholland KE. Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: a systematic review and meta-analysis of controlled clinical trials. Epidemiol Infect. 2012;140:1343–55. doi:10.1017/S0950268812000957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S0950268812000957</ArticleId>
            <ArticleId IdType="pmc">PMC3404480</ArticleId>
            <ArticleId IdType="pubmed">22583474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monasta L, Ronfani L, Marchetti F, Montico M, Vecchi Brumatti L, Bavcar A, Grasso D, Barbiero C, Tamburlini G. Burden of disease caused by otitis media: systematic review and global estimates. PLoS One. 2012;7:e36226. doi:10.1371/journal.pone.0036226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0036226</ArticleId>
            <ArticleId IdType="pmc">PMC3340347</ArticleId>
            <ArticleId IdType="pubmed">22558393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alderson MR. Status of research and development of pediatric vaccines for Streptococcus pneumoniae. Vaccine. 2016;34:2959–61. doi:10.1016/j.vaccine.2016.03.107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2016.03.107</ArticleId>
            <ArticleId IdType="pmc">PMC4906266</ArticleId>
            <ArticleId IdType="pubmed">27083428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12:e0177113. doi:10.1371/journal.pone.0177113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0177113</ArticleId>
            <ArticleId IdType="pmc">PMC5423631</ArticleId>
            <ArticleId IdType="pubmed">28486544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lagousi T, Basdeki P, Routsias J, Spoulou V. Novel protein-based pneumococcal vaccines: assessing the use of distinct protein fragments instead of full-length proteins as vaccine antigens. Vaccines (Basel). 2019;7:9. doi:10.3390/vaccines7010009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/vaccines7010009</ArticleId>
            <ArticleId IdType="pmc">PMC6466302</ArticleId>
            <ArticleId IdType="pubmed">30669439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borrow R, Dagan R, Zepp F, Hallander H, Poolman J. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines. 2011;10:1621–31. doi:10.1586/erv.11.142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/erv.11.142</ArticleId>
            <ArticleId IdType="pubmed">22043960</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
